

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**偉俊生物科技有限公司\***  
**Wai Chun Bio-Technology Limited**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 660)**

**DELAY IN PUBLICATION OF 2019 ANNUAL RESULTS; AND  
SUSPENSION OF TRADING**

This announcement is made by Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09 and 13.49(3) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) announces that due to the outbreak of the novel coronavirus disease (COVID-19) epidemic in the People’s Republic of China, the finalisation of the unaudited consolidated management accounts of the Group for the year ended 31 December 2019 (the “**Management Accounts**”) and the reporting and audit processes of the Group’s consolidated financial statements for the year ended 31 December 2019 (the “**2019 Annual Results**”) have been affected and delayed. Accordingly, the publication of the audited consolidated annual results announcement of the Group for the year ended 31 December 2019 is inevitably delayed.

Taking into account the Management Accounts still in the preparation process and once the Management Accounts being finalized, the auditors of the Company will require time to complete all of its audit procedures for the Management Accounts. The Board considers that it would not be practicable to issue the Management Accounts. The Company is in constant liaison with the auditors to monitor the situation. If there are other material developments in the completion of the audit process, further announcement will be made by the Company as and when necessary. Following the completion of the audit process, the Company will publish the 2019 audited annual results announcement as agreed by the Company’s auditors and the annual report for the year ended 31 December 2019 as soon as practicable.

The Company will schedule another meeting of the Board to approve the 2019 Annual Results and will publish further announcement(s) in due course to inform the shareholders of the Company about the date of the meeting of the Board.

## **SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended with effect from 9:00 a.m. on Wednesday, 1 April 2020 pending the release of the announcement of 2019 Annual Results. The Board expects the 2019 Annual Results will be announced not later than 31 May 2020. An application will then be immediately made by the Company to the Stock Exchange for resumption of trading in the shares.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Wai Chun Bio-Technology Limited**  
Lam Ching Kui  
*Chairman and Chief Executive Officer*

Hong Kong, 31 March 2020

*As at the date of this announcement, the Board comprises one executive Director, namely Mr. Lam Ching Kui (Chairman and Chief Executive Officer), and three independent non-executive Directors, namely Mr. Chan Chun Wai, Tony, Mr. Hau Pak Man and Mr. Li Jinyuan.*

*\*for identification purpose only*